MediciNova Announces Topline Results from MN-001-NATG-202 Clinical Trial of MN-001 (Tipelukast)

MediciNova reported topline results from its Phase 2 MN-001-NATG-202 trial evaluating MN-001 (tipelukast) for treating hypertriglyceridemia and NAFLD in type 2 diabetes patients. The drug showed statistically significant increases in HDL-C and HDL-P, significant early triglyceride reduction at Week 4, and numerical improvements in body weight and liver fat. MN-001 demonstrated a favorable safety profile, though the company indicated a larger study is needed to further evaluate efficacy.